Common TitleACTG 229
Official Title Double-Blind, Randomized, Phase II Study of Saquinavir (Ro 31-8959) Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (Dideoxycytidine; ddC) Versus Saquinavir (Ro 31-8959) Plus AZT Plus ddC
Phase Phase II
ClinicalTrials.gov NCT00001040
Treatments
Saquinavir
Saquinavir
Tradename:InviraseOther Names:SQVClass:Protease Inhibitors (PI)Categories Treatment-ExperiencedDual TherapyResistance/Virological FailurePharmacologyGeneral Pharmacology
Funding
Non-IndustryNational Institute of Allergy and Infectious Diseases (NIAID)
References
- Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med. 1996;334:1011-7.
- Schapiro JM, Lawrence J, Speck R, et al. Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229. J Infect Dis. 1999;179:249-53.
- Vanhove GF, Gries JM, Verotta D, et al. Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother. 1997;41:2433-8.